Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Pharmacology. 2011;88(5-6):242-4. doi: 10.1159/000331866. Epub 2011 Oct 12.
Pemetrexed-induced immune hemolytic anemia is a rare acute complication and a potentially life-threatening syndrome. Here we report a case of severe hemolytic anemia induced by pemetrexed in a 67-year-old man with lung adenocarcinoma. Hemoglobin concentration reached a nadir of 6.8 g/dl after 6 days of pemetrexed initiation. Pemetrexed was discontinued and the patient was given a transfusion of red blood cells. The direct antiglobulin test was positive (anti-IgG = 4+, anti-C3d = 2+). The patient's plasma reacted with pemetrexed-treated red blood cells by the immune complex test.
培美曲塞引起的免疫性溶血性贫血是一种罕见的急性并发症，也是一种潜在的危及生命的综合征。在这里，我们报告了一例 67 岁男性肺腺癌患者在使用培美曲塞后发生严重溶血性贫血的病例。在开始使用培美曲塞 6 天后，血红蛋白浓度降至 6.8 g/dl 的最低点。停用培美曲塞，并给患者输注红细胞。直接抗球蛋白试验阳性（抗 IgG = 4+，抗 C3d = 2+）。免疫复合物试验显示患者的血浆与经培美曲塞处理的红细胞发生反应。
